Abaloparatide

World Peptide Foundation

Where is Abaloparatide being studied?

Find registered human studies, phases, products, recruitment status and reported research locations around the world. Registry search matches are separate from this profile’s reviewed evidence.

Find studies for Abaloparatide →Worldwide registry directory

Scientific intelligence record

Experience 2.0

PTHrP analog

Abaloparatide is a synthetic 34-residue analog of human parathyroid hormone-related protein, PTHrP(1–34), designed to activate the parathyroid hormone type 1 receptor. Intermittent subcutaneous exposure produces an osteoanabolic response by stimulating osteoblast activity and increasing bone formation. The molecule contains an α-aminoisobutyric-acid substitution and is distinct from endogenous PTHrP and from teriparatide. Regulatory authorization is product- and jurisdiction-specific: the FDA-approved TYMLOS label covers defined high-fracture-risk postmenopausal women and men, while the EMA-authorized ELADYNOS indication is for postmenopausal women at increased fracture risk.

Record status

Traceability partial

Last meaningful update: 9/20/2026

Evidence searched through:: Not recorded
Assessment updated:: 9/20/2026
Documented human review:: 9/20/2026
Automated scientific assessment:: None recorded
AI source check:: 9/26/2026

Published source links and profile text pass separate gates. Only a documented human review is labelled as human review; an automated scientific assessment applies deterministic checks, and an AI source check confirms only that a source exists and matches its identifiers. A source count alone does not establish a review.

Evidence coverage has three distinct layers. The corpus count is a transparent screening inventory, the featured set contains study-level tiering and interpretation, and the published-source count contains records promoted through the institutional publication workflow. Source validation, editorial publication, and scientific appraisal are separate decisions; these numbers must not be merged.

Ranked research corpus

454

Categorized publications with provisional ranking; scientific review remains separate.

Featured tiered studies

Cornerstone publications with study-level interpretation, limitations, and tier disclosure.

Research domains

Clinical and scientific questions synthesized independently across the evidence atlas.

Published source records

Database records promoted through the governed publication workflow—not the corpus total.

Corpus generated 2026-09-18. Counts remain separately labeled so screening is not represented as completed review.

Human experience · separate evidence stream

No community pattern is displayed yet

Eligible observations remain below the privacy and reliability threshold. WPF will not convert a handful of reports into a percentage, trend, or clinical claim.

Observation is valuable human context. It is not evidence of causation, efficacy, or safety.

Public display gate

n ≥ 20 eligible observations

Exact progress remains private before the threshold.

Contribute an observation Archive details

Intelligence snapshot

The state of the record

A compact view of what is represented, what remains unresolved, and how completely the record can be traced.

Ranked research corpus

454

Categorized screening records; proposed rankings remain pending human appraisal.

Featured tiered studies

Cornerstone studies with published study-level interpretation and tier disclosure.

Research domains

Independent evidence dossiers covering the major research questions.

Published source records

Source records published through the governed workflow; this count does not certify scientific conclusions.

Contradictions

Conflicting evidence relationships that remain visible.

Research gaps

Questions the current record identifies as unresolved.

Connected media

Media records explicitly linked to this scientific record.

What we know

Evidence, claims, and boundaries

The project separates represented evidence from qualification, contradiction, uncertainty, and what the evidence does not establish.

Reconciled domain conclusions

6 published domain syntheses connected to 0 featured studies

Abaloparatide no longer relies on the legacy “no public claim” state. Each research domain publishes a bounded synthesis, confidence level, evidence context, limitations, geographic applicability, regulatory interpretation, and research gaps. Publication of these syntheses is separate from the scientific review status shown above.

Inspect the reconciled evidence atlas

Evidence boundary

Featured evidence

Domain links

See graph

Contradicting

With explicit limits

What this does not establish

• The governed corpus includes the pivotal ACTIVE randomized phase 3 trial, histomorphometry and fracture analyses, the ACTIVExtend antiresorptive-sequencing study, trials in men and Japanese populations, a transdermal formulation trial, real-world comparative research, systematic reviews and network meta-analyses, and mechanistic or preclinical work. Source identities, titles, authorship, publication metadata, DOI/PMID links, peptide identity, and duplication were checked against PubMed. Evidence lanes and strength grades are provisional and preserve study-design boundaries; detailed claim-level risk-of-bias, applicability, and contradiction review remains part of accountable Owner review.
• Most fracture-outcome evidence comes from selected trial populations, especially postmenopausal women, and may not generalize to every patient with osteoporosis. Some studies use bone-mineral density or bone-turnover markers rather than fracture endpoints; indirect comparisons cannot replace adequately powered head-to-head trials. Sponsorship, formulation differences, adherence, background calcium or vitamin D, subsequent antiresorptive therapy, renal function, baseline fracture risk, and jurisdictional labeling affect interpretation. Long-duration human data are limited; rare risks and postmarketing events cannot be fully characterized by preauthorization trials. Current product labeling—not this profile—controls contraindications, warnings, duration, and clinical use.
• The presence of published evidence does not by itself establish safety, efficacy, causation or clinical benefit.

Inspect the published evidence record25 governed records · titles, provenance, and original-source linksOpen records ↓

2020Phase 3 human evidence

Evidence strength A · 90/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness: 80/100
Replication: 65/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis.

The ACTIVE study demonstrated the antifracture efficacy of abaloparatide in postmenopausal women with osteoporosis.

Authors: Benjamin Z Leder, Bruce Mitlak, Ming-Yi Hu, Gary Hattersley, Richard S Bockman
Source: The Journal of clinical endocrinology and metabolism
DOI: 10.1210/clinem/dgz162
PubMed: 31674644

Open original source

2016Phase 3 human evidence

Evidence strength A · 90/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Directness: 80/100
Replication: 65/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.

Additional therapies are needed for prevention of osteoporotic fractures.

Authors: Paul D Miller, Gary Hattersley, Bente Juel Riis, Gregory C Williams, Edith Lau, Luis Augusto Russo, Peter Alexandersen, Cristiano A F Zerbini, Ming-yi Hu, Alan G Harris, Lorraine A Fitzpatrick, Felicia Cosman
Source: JAMA
DOI: 10.1001/jama.2016.11136
PubMed: 27533157

Open original source

2017Phase 3 human evidence

Evidence strength A · 90/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Directness: 80/100
Replication: 65/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: The ACTIVE phase 3 trial.

There are a number of effective treatments for osteoporosis but most are in the antiresorptive class of compounds.

Authors: Carolina A Moreira, Lorraine A Fitzpatrick, Yamei Wang, Robert R Recker
Source: Bone
DOI: 10.1016/j.bone.2016.11.004
PubMed: 27826127

Open original source

2023Phase 3 human evidence

Evidence strength A · 90/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Directness: 80/100
Replication: 65/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

The effects of abaloparatide on hip geometry and biomechanical properties in Japanese osteoporotic patients assessed using DXA-based hip structural analysis: results of the Japanese phase 3 ACTIVE-J trial.

Daily subcutaneous injection of 80 μg abaloparatide increased bone mineral density in Japanese patients with osteoporosis at high fracture risk in the ACTIVE-J trial.

Authors: Teruki Sone, Kazuhiro Ohnaru, Takumi Sugai, Akiko Yamashita, Nobukazu Okimoto, Tetsuo Inoue, Toshio Matsumoto
Source: Archives of osteoporosis
DOI: 10.1007/s11657-023-01344-5
PubMed: 38030806

Open original source

2025Phase 3 human evidence

Evidence strength A · 90/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Directness: 80/100
Replication: 65/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Bone turnover markers predict changes in bone mineral density in men treated with abaloparatide: results from the abaloparatide for the treatment of men with osteoporosis (ATOM) study.

Early increases in bone turnover markers (BTMs) in response to anabolic therapy correlate with 18-mo BMD increases in postmenopausal women with osteoporosis; however, this relationship has not been assessed in men.

Authors: Richard Eastell, Jacques P Brown, Robert A Adler, E Michael Lewiecki, Neil Binkley, Eric S Orwoll, David Kendler, Bruce H Mitlak, Yamei Wang
Source: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
DOI: 10.1093/jbmr/zjaf003
PubMed: 39791502

Open original source

2024Phase 3 human evidence

Evidence strength A · 90/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Directness: 80/100
Replication: 65/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Effects of Abaloparatide on Bone Mineral Density in Proximal Femoral Regions Corresponding to Arthroplasty Gruen Zones: A Study of Postmenopausal Women with Osteoporosis.

Low hip bone mineral density (BMD) in patients who undergo total hip arthroplasty (THA) increases the risk of periprosthetic fractures, implant instability, and other complications.

Authors: Neil P Sheth, James Russell Smith, Renaud Winzenrieth, Ludovic Humbert, Yamei Wang, John I Boxberger, Mathias P Bostrom
Source: The Journal of bone and joint surgery. American volume
DOI: 10.2106/jbjs.23.01334
PubMed: 38691582

Open original source

2022Phase 1–2 human evidence

Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Directness: 80/100
Replication: 65/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial.

Abaloparatide significantly increased bone mineral density (BMD) in women with postmenopausal osteoporosis and decreased risk of vertebral, nonvertebral, and clinical fractures compared with placebo.

Authors: Edward Czerwinski, Jose Cardona, Rafal Plebanski, Chris Recknor, Tamara Vokes, Kenneth G Saag, Neil Binkley, E Michael Lewiecki, Jonathan Adachi, Dorota Knychas, David Kendler, Eric Orwoll
Source: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
DOI: 10.1002/jbmr.4719
PubMed: 36190391

Open original source

2018Phase 1–2 human evidence

Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Directness: 80/100
Replication: 65/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis.

In women with postmenopausal osteoporosis, we investigated the effects of 24 months of treatment with alendronate (ALN) following 18 months of treatment with abaloparatide (ABL) or placebo (PBO).

Authors: Henry G Bone, Felicia Cosman, Paul D Miller, Gregory C Williams, Gary Hattersley, Ming-Yi Hu, Lorraine A Fitzpatrick, Bruce Mitlak, Socrates Papapoulos, René Rizzoli, Robin K Dore, John P Bilezikian
Source: The Journal of clinical endocrinology and metabolism
DOI: 10.1210/jc.2018-00163
PubMed: 29800372

Open original source

2025Phase 1–2 human evidence

Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Directness: 80/100
Replication: 65/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Probability of achieving bone mineral density treatment targets with abaloparatide and teriparatide.

The goal of treatment for women at high risk of fracture who have a T-score ≤-2.5 is to mitigate fracture risk by achieving T-scores at least above -2.5.

Authors: Felicia Cosman, Bruce H Mitlak, Yamei Wang, Leny Pearman, Carolina A Moreira, E Michael Lewiecki, Steven R Cummings
Source: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
DOI: 10.1093/jbmr/zjaf053
PubMed: 40214193

Open original source

2023Phase 1–2 human evidence

Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Directness: 80/100
Replication: 65/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Abaloparatide dose-dependently increases bone mineral density in postmenopausal women with osteoporosis: a phase 2 study.

This study aimed to determine the efficacy of abaloparatide in increasing bone mineral density (BMD) and its safety in postmenopausal Japanese women with osteoporosis.

Authors: Toshio Matsumoto, Teruki Sone, Akiko Yamashita, Tetsuo Inoue
Source: Journal of bone and mineral metabolism
DOI: 10.1007/s00774-023-01455-6
PubMed: 37505256

Open original source

2023Phase 1–2 human evidence

Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Directness: 80/100
Replication: 65/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Efficacy and Safety of Transdermal Abaloparatide in Postmenopausal Women with Osteoporosis: A Randomized Study.

Anabolic therapies, recommended for patients at very high fracture risk, are administered subcutaneously (SC).

Authors: E Michael Lewiecki, Edward Czerwinski, Chris Recknor, Anna Strzelecka, Guillermo Valenzuela, Mary Lawrence, Stuart Silverman, Jose Cardona, Susan M Nattrass, Neil Binkley, Miriam Annett, Leny Pearman
Source: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
DOI: 10.1002/jbmr.4877
PubMed: 37417725

Open original source

2017Observational human evidence

Evidence strength B · 70/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Directness: 80/100
Replication: 65/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis.

Abaloparatide (previously known as BA058) is a synthetic 34-amino acid peptide and novel selective activator of parathyroid hormone receptor 1 (PTHR1) currently under development as a new anabolic agent in the management of osteoporosis.

Authors: Sri Harsha Tella, Anuhya Kommalapati, Ricardo Correa
Source: Cureus
DOI: 10.7759/cureus.1300
PubMed: 28680788

Open original source

2017Observational human evidence

Evidence strength C · 65/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Directness: 80/100
Replication: 65/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Abaloparatide: First Global Approval.

Abaloparatide (Tymlos™) is a synthetic peptide analogue of human parathyroid hormone-related protein that was developed by Radius Health as an osteoanabolic agent for the treatment of postmenopausal osteoporosis.

Authors: Matt Shirley
Source: Drugs
DOI: 10.1007/s40265-017-0780-7
PubMed: 28624872

Open original source

2023Observational human evidence

Evidence strength A · 88/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Directness: 65/100
Replication: 65/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Evidence for the cardiovascular effects of osteoporosis treatments in randomized trials of post-menopausal women: A systematic review and Bayesian network meta-analysis.

Osteoporosis medications have been reported to have beneficial and harmful cardiovascular effects.

Authors: Alexander H Seeto, Mina Tadrous, Abadi K Gebre, Joshua R Lewis, Howard A Fink, Peter R Ebeling, Alexander J Rodríguez
Source: Bone
DOI: 10.1016/j.bone.2022.116610
PubMed: 36372197

Open original source

2023Observational human evidence

Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials.

To review the comparative effectiveness of osteoporosis treatments, including the bone anabolic agents, abaloparatide and romosozumab, on reducing the risk of fractures in postmenopausal women, and to characterise the effect of antiosteoporosis drug treatments on the risk of fractures according to baseline risk factors.

Authors: Mina Nicole Händel, Isabel Cardoso, Cecilie von Bülow, Jeanett Friis Rohde, Anja Ussing, Sabrina Mai Nielsen, Robin Christensen, Jean-Jacques Body, Maria Luisa Brandi, Adolfo Diez-Perez, Peyman Hadji, Muhammad Kassim Javaid
Source: BMJ (Clinical research ed.)
DOI: 10.1136/bmj-2021-068033
PubMed: 37130601

Open original source

2025Observational human evidence

Evidence strength B · 76/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Directness: 80/100
Replication: 65/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Comparative Effectiveness of Abaloparatide and Teriparatide in Women 50 Years of Age and Older: Update of a Real-World Retrospective Analysis.

Abaloparatide and teriparatide are osteoanabolic treatments indicated for postmenopausal women and men with osteoporosis at high risk of fracture.

Authors: Laila Tabatabai, Felicia Cosman, Jeffrey R Curtis, Kristi T DeSapri, Clayton T LaBaume, Jean-Yves Reginster, René Rizzoli, Bernard Cortet, Yamei Wang, Joseph Chiodo, Bruce H Mitlak
Source: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
DOI: 10.1016/j.eprac.2024.10.017
PubMed: 39551187

Open original source

2024Observational human evidence

Evidence strength A · 88/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Directness: 80/100
Replication: 65/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

The Safety and Efficacy of Abaloparatide on Postmenopausal Osteoporosis: A Systematic Review and Meta-analysis.

The aging of the population increases the incidence of postmenopausal osteoporosis, which threatens the health of elderly women.

Authors: Fuxin Xu, Yurun Wang, Xinjian Zhu
Source: Clinical therapeutics
DOI: 10.1016/j.clinthera.2023.12.010
PubMed: 38307725

Open original source

2025Observational human evidence

Evidence strength A · 88/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Directness: 65/100
Replication: 65/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis.

Osteoporosis, defined by reduced bone mineral density and macro- and micro-architectural degradation, leads to increased fracture risk, particularly in aging populations.

Authors: Charlotte Beaudart, Nicola Veronese, Jonathan Douxfils, Jotheeswaran Amuthavalli Thiyagarajan, Francesco Bolzetta, Paolo Albanese, Gianpaolo Voltan, Majed Alokail, Nicholas C Harvey, Nicholas R Fuggle, Olivier Bruyère, René Rizzoli
Source: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
DOI: 10.1007/s00198-025-07440-1
PubMed: 40047881

Open original source

2019Observational human evidence

Evidence strength A · 88/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Directness: 65/100
Replication: 65/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis.

Osteoporosis and osteopenia are associated with increased fracture incidence in postmenopausal women.

Authors: Patricia Barrionuevo, Ekta Kapoor, Noor Asi, Fares Alahdab, Khaled Mohammed, Khalid Benkhadra, Jehad Almasri, Wigdan Farah, Maria Sarigianni, Kalpana Muthusamy, Alaa Al Nofal, Qusay Haydour
Source: The Journal of clinical endocrinology and metabolism
DOI: 10.1210/jc.2019-00192
PubMed: 30907957

Open original source

2023Observational human evidence

Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.

The prevalence of osteoporosis is increasing in the United States.

Authors: Chelsea Ayers, Devan Kansagara, Brittany Lazur, Rongwei Fu, Amy Kwon, Curtis Harrod
Source: Annals of internal medicine
DOI: 10.7326/m22-0684
PubMed: 36592455

Open original source

2021Observational human evidence

Evidence strength B · 70/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Directness: 80/100
Replication: 65/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Abaloparatide: A review of preclinical and clinical studies.

Osteoporosis is a debilitating disease characterized by reduced bone mineral density and an increased risk of fractures.

Authors: Mikkel Bo Brent
Source: European journal of pharmacology
DOI: 10.1016/j.ejphar.2021.174409
PubMed: 34364879

Open original source

2019Observational human evidence

Evidence strength C · 70/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Directness: 80/100
Replication: 65/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Abaloparatide, the second generation osteoanabolic drug: Molecular mechanisms underlying its advantages over the first-in-class teriparatide.

Abaloparatide is an analog of human parathyroid hormone-related protein (PTHrP) that has recently been approved for the treatment of post-menopausal osteoporosis.

Authors: Sharmistha Bhattacharyya, Subhashis Pal, Naibedya Chattopadhyay
Source: Biochemical pharmacology
DOI: 10.1016/j.bcp.2019.05.024
PubMed: 31136739

Open original source

2019Observational human evidence

Evidence strength C · 70/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Directness: 80/100
Replication: 65/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Abaloparatide: A new pharmacological option for osteoporosis.

The efficacy and safety of abaloparatide, a parathyroid hormone-related protein analog for the treatment of osteoporosis in postmenopausal women at high fracture risk, is reviewed.

Authors: Allyson Sleeman, Jennifer N Clements
Source: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
DOI: 10.1093/ajhp/zxy022
PubMed: 30689744

Open original source

2018Observational human evidence

Evidence strength C · 70/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Directness: 80/100
Replication: 65/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Abaloparatide: Review of a Next-Generation Parathyroid Hormone Agonist.

To review the efficacy, safety, and economics of abaloparatide in the treatment of postmenopausal osteoporosis.

Authors: Eric G Boyce, Yvonne Mai, Christopher Pham
Source: The Annals of pharmacotherapy
DOI: 10.1177/1060028017748649
PubMed: 29241341

Open original source

2019Laboratory research

Evidence strength C · 62/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Directness: 80/100
Replication: 65/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Precisely Controlled Delivery of Abaloparatide through Injectable Hydrogel to Promote Bone Regeneration.

Side-effects from allograft, limited bone stock, and site morbidity from autograft are the major challenges to traditional bone defect treatments.

Authors: Ziyu Ning, Baoyu Tan, Bo Chen, Dzi Shing Aaron Lau, Tak Man Wong, Tianhao Sun, Songlin Peng, Zhaoyang Li, William Weijia Lu
Source: Macromolecular bioscience
DOI: 10.1002/mabi.201900020
PubMed: 31066995

Open original source

Scientific context

Chemistry and represented biological context

Existing reviewed chemistry is preserved as scientific context. Chemistry and mechanism information do not establish clinical efficacy or safety.

Open chemistry and biological context ↓

Chemical identity

Molecular and structural record

Structured record

Molecular formula: C174H300N56O49
Molecular weight (Da): 3961
Amino acid sequence: AVSEHQLLHDKGKSIQDLRRRELLEKLLXKLHTA-NH2
InChIKey: BVISQZFBLRSESR-XSCWXTNMSA-N

Chemical identity describes the recorded molecular information. It does not establish biological activity, clinical efficacy, safety, or therapeutic suitability.

Explore further

Continue through the research system

Move from this peptide record into the project's broader evidence, research, comparison, and methodology systems.

Compare peptides

Examine represented peptide records side by side.

Evidence system

Explore how scientific evidence is represented and reviewed.

Research hub

Enter the broader research and intelligence environment.

Methodology

Review project methods, boundaries, and interpretation rules.

Research

How the scientific record is developing

Chronology, unresolved research questions, opportunities, and researcher activity remain descriptive rather than evaluative.

Research chronology

2016 · study · Temporal status not established
Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
JAMA
2017 · study · Temporal status not established
Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: The ACTIVE phase 3 trial.
Bone
2017 · study · Temporal status not established
Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis.
Cureus
2017 · study · Temporal status not established
Abaloparatide: First Global Approval.
Drugs
2018 · study · Temporal status not established
ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis.
The Journal of clinical endocrinology and metabolism
2018 · study · Temporal status not established
Abaloparatide: Review of a Next-Generation Parathyroid Hormone Agonist.
The Annals of pharmacotherapy
2019 · study · Temporal status not established
Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis.
The Journal of clinical endocrinology and metabolism
2019 · study · Temporal status not established
Abaloparatide, the second generation osteoanabolic drug: Molecular mechanisms underlying its advantages over the first-in-class teriparatide.
Biochemical pharmacology
2019 · study · Temporal status not established
Abaloparatide: A new pharmacological option for osteoporosis.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
2019 · study · Temporal status not established
Precisely Controlled Delivery of Abaloparatide through Injectable Hydrogel to Promote Bone Regeneration.
Macromolecular bioscience
2020 · study · Temporal status not established
Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis.
The Journal of clinical endocrinology and metabolism
2021 · study · Temporal status not established
Abaloparatide: A review of preclinical and clinical studies.
European journal of pharmacology
2022 · study · Temporal status not established
The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
2023 · study · Temporal status not established
The effects of abaloparatide on hip geometry and biomechanical properties in Japanese osteoporotic patients assessed using DXA-based hip structural analysis: results of the Japanese phase 3 ACTIVE-J trial.
Archives of osteoporosis
2023 · study · Temporal status not established
Abaloparatide dose-dependently increases bone mineral density in postmenopausal women with osteoporosis: a phase 2 study.
Journal of bone and mineral metabolism
2023 · study · Temporal status not established
Efficacy and Safety of Transdermal Abaloparatide in Postmenopausal Women with Osteoporosis: A Randomized Study.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
2023 · study · Temporal status not established
Evidence for the cardiovascular effects of osteoporosis treatments in randomized trials of post-menopausal women: A systematic review and Bayesian network meta-analysis.
Bone
2023 · study · Temporal status not established
Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials.
BMJ (Clinical research ed.)
2023 · study · Temporal status not established
Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
Annals of internal medicine
2024 · study · Temporal status not established
Effects of Abaloparatide on Bone Mineral Density in Proximal Femoral Regions Corresponding to Arthroplasty Gruen Zones: A Study of Postmenopausal Women with Osteoporosis.
The Journal of bone and joint surgery. American volume
2024 · study · Temporal status not established
The Safety and Efficacy of Abaloparatide on Postmenopausal Osteoporosis: A Systematic Review and Meta-analysis.
Clinical therapeutics
2025 · study · Temporal status not established
Bone turnover markers predict changes in bone mineral density in men treated with abaloparatide: results from the abaloparatide for the treatment of men with osteoporosis (ATOM) study.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
2025 · study · Temporal status not established
Probability of achieving bone mineral density treatment targets with abaloparatide and teriparatide.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
2025 · study · Temporal status not established
Comparative Effectiveness of Abaloparatide and Teriparatide in Women 50 Years of Age and Older: Update of a Real-World Retrospective Analysis.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
2025 · study · Temporal status not established
PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
2026 · regulatory · Temporal status not established
Regulatory review: approved
European Union (EMA)
2026 · regulatory · Temporal status not established
Regulatory review: approved
United States (FDA)

The represented chronology reflects records currently included in the governed dataset and does not claim to represent the entire scientific literature.

What still needs investigation

Claim traceability

Edward Czerwinski

2 represented evidence records

Years represented: 2022, 2023

Publishing organizations appearing in records: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Connections

Follow the scientific relationships

Connections appear only when they are represented by the project’s underlying records.

Reviewer provenance state

“Human scientist reviewed: no” means that specific source-path attribution is not recorded. It does not silently negate the separate publication-review state.

Domain conclusion → Evidence

Connected

Evidence → Source

Connected

Source → Original record

Connected

Traceability documents how the project connects statements to records. It does not establish that a source is scientifically valid or that a claim is clinically true.

Reconciled for 6 domain conclusions and 0 featured studies.

Detailed study-to-domain mappings and original-source paths appear in the Abaloparatide evidence-governance section.

Inspect the ranked source records

Observational archive

What contributors reported

Observational archive data is intentionally separated from published scientific evidence.

Observational boundary

Insufficient eligible observations are available for display under the current filters.

Insufficient eligible observations are currently represented to display aggregated findings for this peptide.

Regulatory context

Published jurisdictional records

Regulatory status is jurisdiction-specific and time-dependent. It is presented as context, not as a recommendation for use or a substitute for scientific evidence evaluation.

European Union (EMA)

Regulator: EMA

approved

As of: 9/9/2026 · Temporal status not established

EMA EPAR — Eladynos (EMEA/H/C/005928)

United States (FDA)

Regulator: FDA

approved

As of: 9/9/2026 · Temporal status not established

FDA Drugs@FDA NDA 208743 and TYMLOS Prescribing Information, revised August 2026

Research + media

Media connected to this scientific record

Only media explicitly linked through the project’s relationship system appears here.

No scientifically connected media is currently represented for this peptide.

Sources + provenance

Read the scientific record with its boundaries intact

The public record organizes reviewed evidence; it does not establish scientific truth by itself.

Association, mechanism, observation and regulatory status must not be represented as proof of clinical efficacy or safety.

Observational reports describe contributor experiences and cannot establish causation, effectiveness, safety or clinical benefit.

Contradictory and qualifying evidence must remain visible rather than being silently discarded.

Absence of represented evidence is not evidence that research does not exist.

Research gaps identify unresolved questions; they are not negative conclusions.

Regulatory status is distinct from scientific evidence quality.

Media relationships provide context and explanation; they do not increase the strength of scientific evidence.

A section with no represented records is an incomplete project record, not a scientific conclusion.

Researcher and institutional relationships are shown only when supported by represented records and must not be interpreted as rankings or endorsements.

Generated: 11/8/2026, 5:24:49 PM

global evidence atlas

Abaloparatide research, ranked and separated by purpose

This is a deduplicated literature screening registry—not a claim that every mention directly proves efficacy or safety. Machine proposals remain visibly separate from governed human appraisal.

454Discoverable source universe

454Ranked screening records

6Research domains

0Accountably approved conclusions

SearchDomainEvidence class

Abaloparatide: what this atlas does and does not establish

Last checked: 2026-09-18
Accountable publication approval: Not yet approved by a named accountable reviewer. Machine screening only.

No new outcome conclusion is inferred from discovery metadata. Named accountable approval is required for governed scientific conclusions.

Regulatory status by jurisdiction

Absence of a record in this pass is not proof that no authorization exists. Status must remain jurisdiction-, product-, formulation-, and date-specific.

European Union (EMA)approvedchecked 2026-09-09
ELADYNOS (abaloparatide) is centrally authorised in the European Union for treatment of osteoporosis in postmenopausal women at increased risk of fracture.
EMA EPAR — Eladynos (EMEA/H/C/005928)
United States (FDA)approvedchecked 2026-09-09
TYMLOS (abaloparatide) is FDA-approved for treatment of postmenopausal women with osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy, and to increase bone density in men with osteoporosis at high risk for fracture or with the same treatment-history criteria.
FDA Drugs@FDA NDA 208743 and TYMLOS Prescribing Information, revised August 2026

1 FDA structured product label record(s) were identified for this compound name in openFDA. Label presence reflects an approved product exists under that name; it is not a claim about the specific formulation, dose, or use being discussed anywhere else on this page.

No machine-proposed evidence-strength grades exist yet for this compound; all screening records are unassigned pending further review.

Abaloparatide evidence · ranking key

How evidence is ranked

A tier describes the evidentiary role and design strength of a source. It is not a popularity score, proof that every conclusion is correct, or a substitute for claim-level review.

Practice-defining evidence

Large, well-conducted randomized trials; prespecified major outcomes; rigorous systematic reviews or meta-analyses; and major regulatory assessments.

Strong supporting evidence

Smaller randomized trials, strong prospective cohorts, prespecified secondary analyses, and high-quality comparative-effectiveness studies.

Contextual evidence

Retrospective cohorts, claims-database studies, pharmacovigilance analyses, mechanistic human research, and well-documented case series.

Signal-generating evidence

Case reports, conference abstracts, preclinical research, hypothesis-generating analyses, and expert commentary.

Tier and confidence answer different questions

Tier classifies source design and evidentiary role. Confidence reflects risk of bias, sample size, comparator quality, outcome relevance, follow-up, missing data, directness, replication, reporting quality, and whether conclusions stay within the measured results.

Funding and conflicts are disclosed and considered, but sponsorship never automatically changes a tier. Corrections, retractions, and expressions of concern override the original rating.

peptide explorer

Structural visualization and provenance

Evidence-class labeling remains visible even when interactive rendering is unavailable. Representative geometry is not an experimentally determined or predicted biological conformation.

Fully specified molecular identity

Molecular formula: C174H300N56O49
Molecular weight: 3961 g/mol
Exact identity / sequence notation: Ala-Val-Ser-Glu-His-Gln-Leu-Leu-His-Asp-Lys-Gly-Lys-Ser-Ile-Gln-Asp-Leu-Arg-Arg-Arg-Glu-Leu-Leu-Glu-Lys-Leu-Leu-X-Lys-Leu-His-Thr-Ala-NH2
Identity-defining modifications: 34-residue PTHrP analog
Non-standard residue retained as X in viewer
C-terminal amide
PubChem CID: 76943386
InChIKey: BVISQZFBLRSESR-XSCWXTNMSA-N

Complete registered analog identity; viewer geometry is representative only.

Sources: NIH PubChem — Abaloparatide · reviewed 2026-09-17

Representative sequence-derived model

Structure source: Generated from this record's governed amino-acid sequence
Identifier: Not applicable — not a database structure
Method: Schematic layout ordered by residue position only; not a molecular-dynamics, homology, or fold prediction
Confidence / limitations: Illustrative only. Not physically accurate; carries no structural, binding-site, or activity meaning.
Provenance: WPF governed PeptideChemistry record
Retrieved / last reviewed: 2026-09-17

This is a representative, sequence-derived model ordered by residue position only. It is not the peptide's experimentally determined or predicted biological conformation, and it carries no claim about real bond angles, distances, secondary structure, binding sites, or activity.

Suggested citation

APA
World Peptide Foundation. (n.d.). Abaloparatide — Peptide Scientific Intelligence. World Peptide Foundation. (Reviewed September 20, 2026.) https://www.worldpeptidefoundation.org/directory/abaloparatide
AMA / Vancouver
World Peptide Foundation. Abaloparatide — Peptide Scientific Intelligence. World Peptide Foundation website. Reviewed September 20, 2026. https://www.worldpeptidefoundation.org/directory/abaloparatide

Where is Abaloparatide being studied?

Abaloparatide

No community pattern is displayed yet

The state of the record

Evidence, claims, and boundaries

6 published domain syntheses connected to 0 featured studies

Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis.

Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.

Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: The ACTIVE phase 3 trial.

The effects of abaloparatide on hip geometry and biomechanical properties in Japanese osteoporotic patients assessed using DXA-based hip structural analysis: results of the Japanese phase 3 ACTIVE-J trial.

Bone turnover markers predict changes in bone mineral density in men treated with abaloparatide: results from the abaloparatide for the treatment of men with osteoporosis (ATOM) study.

Effects of Abaloparatide on Bone Mineral Density in Proximal Femoral Regions Corresponding to Arthroplasty Gruen Zones: A Study of Postmenopausal Women with Osteoporosis.

The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial.

ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis.

Probability of achieving bone mineral density treatment targets with abaloparatide and teriparatide.

Abaloparatide dose-dependently increases bone mineral density in postmenopausal women with osteoporosis: a phase 2 study.

Efficacy and Safety of Transdermal Abaloparatide in Postmenopausal Women with Osteoporosis: A Randomized Study.

Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis.

Abaloparatide: First Global Approval.

Evidence for the cardiovascular effects of osteoporosis treatments in randomized trials of post-menopausal women: A systematic review and Bayesian network meta-analysis.

Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials.

Comparative Effectiveness of Abaloparatide and Teriparatide in Women 50 Years of Age and Older: Update of a Real-World Retrospective Analysis.

The Safety and Efficacy of Abaloparatide on Postmenopausal Osteoporosis: A Systematic Review and Meta-analysis.

PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis.

Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis.

Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.

Abaloparatide: A review of preclinical and clinical studies.

Abaloparatide, the second generation osteoanabolic drug: Molecular mechanisms underlying its advantages over the first-in-class teriparatide.

Abaloparatide: A new pharmacological option for osteoporosis.

Abaloparatide: Review of a Next-Generation Parathyroid Hormone Agonist.

Precisely Controlled Delivery of Abaloparatide through Injectable Hydrogel to Promote Bone Regeneration.

Chemistry and represented biological context

Molecular and structural record

Continue through the research system

Research discovery

How the scientific record is developing

Research chronology

Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.

Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: The ACTIVE phase 3 trial.

Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis.

Abaloparatide: First Global Approval.

ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis.

Abaloparatide: Review of a Next-Generation Parathyroid Hormone Agonist.

Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis.

Abaloparatide, the second generation osteoanabolic drug: Molecular mechanisms underlying its advantages over the first-in-class teriparatide.

Abaloparatide: A new pharmacological option for osteoporosis.

Precisely Controlled Delivery of Abaloparatide through Injectable Hydrogel to Promote Bone Regeneration.

Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis.

Abaloparatide: A review of preclinical and clinical studies.

The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial.

The effects of abaloparatide on hip geometry and biomechanical properties in Japanese osteoporotic patients assessed using DXA-based hip structural analysis: results of the Japanese phase 3 ACTIVE-J trial.

Abaloparatide dose-dependently increases bone mineral density in postmenopausal women with osteoporosis: a phase 2 study.

Efficacy and Safety of Transdermal Abaloparatide in Postmenopausal Women with Osteoporosis: A Randomized Study.

Evidence for the cardiovascular effects of osteoporosis treatments in randomized trials of post-menopausal women: A systematic review and Bayesian network meta-analysis.

Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials.

Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.

Effects of Abaloparatide on Bone Mineral Density in Proximal Femoral Regions Corresponding to Arthroplasty Gruen Zones: A Study of Postmenopausal Women with Osteoporosis.

The Safety and Efficacy of Abaloparatide on Postmenopausal Osteoporosis: A Systematic Review and Meta-analysis.

Bone turnover markers predict changes in bone mineral density in men treated with abaloparatide: results from the abaloparatide for the treatment of men with osteoporosis (ATOM) study.

Probability of achieving bone mineral density treatment targets with abaloparatide and teriparatide.

Comparative Effectiveness of Abaloparatide and Teriparatide in Women 50 Years of Age and Older: Update of a Real-World Retrospective Analysis.

PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis.

Regulatory review: approved

Regulatory review: approved

What still needs investigation

Claim traceability

E Michael Lewiecki

Felicia Cosman

Gary Hattersley

Lorraine A Fitzpatrick

Ming-Yi Hu

Neil Binkley

Yamei Wang

Bruce Mitlak

Carolina A Moreira

Chris Recknor

David Kendler

Edward Czerwinski

Follow the scientific relationships

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research